Background/Aims: Previous studies in rat models of myocardial ischemia showed that Panax quinquefolium saponins (PQS) could attenuate ischemic/reperfusion injury, increase vessel density and improve cardiac function. In the current study, we examined whether PQS could attenuate myocardial dysfunction in a swine model of chronic myocardial ischemia (CMI). Methods: CMI was established in Bama mini-pigs by placing amroid constrictor on the left anterior descending artery (LAD). Starting from 2 months after the surgery, pigs randomly received PQS (30 mg/kg/day), atorvastatin (1.5 mg/kg/day), or no drug for one month (n=6). A group of pigs receiving sham surgery was included as an additional control. Glucose utilization was assessed with positron emission tomography-computer tomography (PET-CT). Cardiac function was assessed with echocardiography. Myocyte size, nuclear density, and arteriolar density were examined in tissue section obtained from the ischemia area. Potential molecular targets of PQS were identified using proteomic analysis with isobaric tags for relative and absolute quantitation (iTARQ) and network pharmacology. Results: In comparison to the sham controls, pigs implanted with ameroid constrictor had decreased ventricular wall motion, left ventricular ejection fraction (LVEF), and glucose utilization. PQS significantly increased cardiac function and glucose utilization. Arteriole density and myocyte nuclear density were increased. Myocyte diameter was decreased. PQS also attenuated the CMI-induced change of protein 
Introduction
Despite recent advancements in interventional therapies, including coronary artery bypass grafting (CABG) and percutaneous coronary interventions (PCI), coronary artery disease (CAD) remains the leading cause of cardiovascular morbidity and mortality worldwide. Approximately 30% of the patients with CAD suffer from recurrent attacks and are not eligible for CABG or PCI [1] . Inducing angiogenesis represents a promising therapeutic approach in such patients [2] [3] [4] . A variety of strategies, including growth factor, gene therapy, and cell-based therapies, have been shown to be effective in inducing angiogenesis in animal models of CAD, but translation into human use faces many challenges [5] .
Statins, a group of selective inhibitors of 3-hydroxyl-3-methyl coenzyme A (HMG-CoA) reductase, are a widely used in patients with CAD to manage dyslipidemia. In addition to lipidlowering effects, statins also improve ventricular remodeling after myocardial infarction (MI), promote endothelial function, and reduce vascular inflammation [6] [7] [8] . A previous study using a swine model of CMI demonstrated that atorvastatin could promote angiogenesis [9] . In mouse models, atorvastatin could also promote angiogenesis and vascular maturation to enhance hematoma absorption [10] . Simvastatin, another member of the stain family, could promote angiogenesis via activation of Akt kinase and increasing nitrous oxide production in human umbilical vein endothelial cells (HUVECs) and endothelial progenitor cells [11, 12] .
Panax quinquefolius saponins (PQS) are major active components of the stems and leaves of Panax quinquefolius (American ginseng), and has been approved for use (Z20030073) in human subjects for >10 years in China. A previous study from this laboratory demonstrated that PQS could increase the expression of VEGF and βFGF in the ischemic area of myocardium in a rat model of acute myocardial infarction (AMI) [13] . As a step to move towards possible clinical use, we examined the effects of PQS on cardiac function and angiogenesis in a large animal model of CMI.
Materials and Methods

Animals
A total of 32 Bama pigs (4 months of age, 20 ± 5kg; Tianjin Bainong Laboratory Animal Breeding Technology, SCXK [Tianjin] 2015-0002) were used in this study. Pigs were raised using standard chow and water in individual cages under strict veterinary supervision with normal circadian rhythm at 20 ± 2 °C. The study was approved by Animal Review Board of Chinese Academy of Medical Sciences [0082-1-40-G2(X)]. All experiments were conducted in compliance with the state legislations on the ethical use and care of laboratory animals.
Surgical procedure
Pigs were anaesthetized with ketamine hydrochloride (20 mg/kg, im), propofol (0.15 mg/kg/min, iv) and 0.5%-2% isoflurane-oxygen mixture (ventilation). The left anterior descending coronary artery (LAD) was exposed using left thoracotomy in sterile condition. Twenty-six pigs were implanted with ameroid constrictors; the remaining 6 pigs received sham surgery. Pigs received standard postoperative care that included the use of analgesics (fentanyl, 0.003 mg/kg q.d.).
Two months after the surgery, LAD stenosis was verified using coronary angiogram (Fig. S1a) . LAD patency in the sham group was also verified (Fig. S1b) . During the experiment, 4 pigs died during the surgery and another 4 died during anesthesia induction. The rate of accidental death (25%) was consistent with that in previous studies [14] . Treatments At 2 months after the surgery, pigs implanted with ameroid constrictor were randomized to receive atorvastatin (1.5 mg/kg/day), PQS (30 mg/kg/day; from Yi-Sheng Pharmaceutical Co. Ltd., Jilin, China), or no drug for 1 month. Test drugs were mixed in pig chow. The amount of food intake was monitored daily to verify the dosage.
Verification of major PQS constituents in peripheral blood
Plasma concentration of major PQS constituents was determined with liquid chromatograph-mass spectrometry (LC-MS), as previously reported [15] . Representative results are shown in Fig. S2 . The following five constituents were analyzed: pseudo-ginsenoside F11, ginsenoside Rc, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rd (Fig. S3) .
F-fluorodeoxyglucose-positron emission tomography (FDG-PET)
At two month post-surgery (Baseline) and the end of drug treatment, FDG-PET was performed with a cardiac PET scanner (GE, Discovery, Boston, MA, USA). Briefly, pigs were anesthetized with ketamine and valium after overnight fasting. Six IU insulin was given intravenously to control the blood glucose. Twenty minutes later,
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F-FDG (3 mCi) was administered intravenously. Scanning was carried out 1 hour later. The images were analyzed by QGS software (Cedars-Sinai Medical Center, Los Angeles, CA, USA). Standardized quantitative analysis was conducted with FDG-PET-bull's eye views, and mean signal intensity (MSI) was calculated using a 17-segment model [16] Manual fitting was conducted when left ventricular contour and mitral valve plane were impropriate for image interpretation. The results of analysis were obtained according to segmental scoring method standard solution (the American Heart Association) [17] . The max MSI segment was set to 100%, and each segment was calculated automatically in accordance with the max MSI to reflect the regional glucose utilization. Glucose utilization was deemed to be low at MSI<70%. Summed rest score (SRS, the sum of the 17 segments), summed rest score percent (SRS%), perfusion defect extent percent (PDE, %), perfusion defect area (Defect, cm 2 ) and total perfusion defect (TPD, %) were acquired by QPS software. Images were assessed by two experienced experts independently.
Echocardiography Two-dimensional echocardiography was performed to measure global and regional left ventricular function at the baseline and upon the completion of 1-month drug treatment using an ultrasound scanner (EPIQ7; Philips Medical Systems, Andover, MA). The global function of the left ventricular and the regional function of the myocardium were evaluated by left ventricular ejection fraction (LVEF) and systolic wall thickening (WT%), respectively. LVEF was determined from the four-chamber views using a modified Simpson's algorithm. Regional wall thickness was evaluated at end systole and end diastole individually on two-dimensional echocardiograms. Left ventricular wall thickness at end-diastole (DWT) and end-systole (SWT) was measured to calculate the WT% (SWT-DWT) / DWT×100%. The analysis was carried out by two experienced ultrasound technicians blinded to the treatment assignment independently.
Tissue harvest and histological examination
Pigs were euthanized with iv injection of saturated potassium chloride solution. The area at risk (AAR) in the LAD territory was collected. Remaining tissues were snap-frozen in liquid nitrogen.
Arteriole density
The AAR in the LAD territory was fixed in 4% paraformaldehyde for 24 h and paraffin-embedded. Slices (5 μm) were incubated with a mouse anti-αSMA (Lifespan, WA, USA) to identify arterioles. Anti-mouse IgG Fab2 Alexa Fluor (1:400) (Cell Signaling, Boston, MA) was used as secondary antibodies. Nuclei were counter-stained with DAPI. To determine arteriole density, 6 random fields per slide were captured at 200× magnification using a fluorescent microscope [18] . Blood vessels with a diameter <100 μm were counted by two independent examiners. Results are expressed as the number of vessels per field. Myocyte nuclear density and morphometry Periodic Acid-Schiff (PAS) stained sections were used to quantify myocyte diameter in AAR myocardium [19] . Myocyte diameter was calculated by counting at least 100 cells from AAR myocardium. Myocytes were counted regardless of size as long as myofilaments surrounding the nucleus could be identified. We also assessed myocyte nuclear density as previously described [20] .
Proteomic analysis
Detailed proteomic operation and data analysis are described in supplementary material online (For all supplemental material see www.karger.com/10.1159/000493407/).
Network pharmacology analysis
Structural information of the 5 compounds in PQS were obtained from PubChem [21] , and submitted to analysis using the BATMAN-TCM bioinformatic analysis platform [22] . This drug target prediction method ranks putative drug-target interactions based on their similarity to the known drug-target interactions [23] . Only the target proteins with top 1% predictions score were considered (Table S1 ). Three validation strategies were applied to evaluate the performance of the prediction model [22] : "leave-one-interactionout" cross-validation, "leave-one-drug-out" cross-validation, and validation of the independent test set. Two types of nodes, including chemical compounds and the corresponding putative targets were predicted. Cytoscape (version 3.4.0) was utilized to visualize the drug/target interaction.
Western blot
Myocardium tissue in AAR (about 200 mg) was homogenized. Proteins were separated on 8% SDS-PAGE and transferred to PVDF membrane (Millipore, Temecula, CA, USA). The membrane was incubated overnight at 4°C with an antibody against PRKCD (1:1000, Lifespan Biotechnology) or GAPDH (1:1000, Santa Cruz Biotechnology, Dallas, TX, USA), and then with horseradish peroxidase-conjugated secondary antibody (1:1000) for 1 hour at room temperature. The images were captured using a Quantity One Image Analyzer (Bio-Rad, USA).
Immunohistochemistry analysis
Tissue sections were stained with an anti-PRKCD antibody (1:50, Lifespan Biotechnology), followed by an HRP-conjugated secondary antibody. Cells with brown granular diaminobenzidine (DAB) reaction in the cytoplasm were considered as positive.
Statistical analysis
Data are represented as mean ± SEM and baseline data were analyzed using one-way analysis of variance (ANOVA), followed by Bonferroni posthoc analysis. Variables after drug treatment were analyzed with one-way analysis of covariance (ANCOVA). The SPSS (version 18.0; Chicago, IL) was used for analyses. P <0.05 was considered statistically significant.
Results
PQS promoted cardiac function in pig mode of CMI
Echocardiography showed that, in comparison to the subjects receiving sham surgery, LVEF% was significantly lowered in all subjects receiving the ameroid constrictor (P=0.001 for both PQS and atorvastatin; P=0.0002 for untreated; Fig. 1a) . In comparison to subjects receiving amroid constrictor but no drug treatment, both PQS and atorvastatin increased LVEF (P=0.009 and 0.018 for PQS and atorvastatin, respectively; Fig. 1b) . Left ventricular systolic WT reduction induced by CMI was attenuated by both PQS and atorvastatin (P=0.00009 and 0.045 for PQS and atorvastatin, respectively; Fig. 1c ). The effect of PQS was more robust than atorvastatin (P=0.017).
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PQS improved myocardial glucose utilization in pig model of CMI
In comparison to subjects receiving sham surgery, SRS, SRS%, TPD% and PDE% were significantly increased in subjects receiving ameroid constrictor after the surgery (P<0.0001 for all, Fig. 2a-d) . SRS and TPD% were decreased by PQS (P=0.012 and 0.003, respectively) as well as atorvastatin (P=0.047 and 0.011, respectively). SRS% and PDE% were decreased by PQS (P=0.004 and 0.013, respectively), but not by atorvastatin (Fig.  2b/d) .
CMI-induced reduction of MSI of mid-anteroseptal, apical septal, apical anterior, and apical inferior segments After two months, pigs subjected to sham operation or ameroid constrictor u n d e r w e n t echocardiography analysis for heart function. Pigs were subsequently treated with atorvastatin or PQS for one month. 3a-e) .
PQS increased arteriole density and myocyte nuclear density, and reduced myocyte diameter Arteriole density in the ischemic myocardium was increased by both PQS and atorvastatin (P=0.00013 and 0.009, respectively; Fig.  4a ). The arteriole number was significantly higher in subjects receiving PQS than with atorvastatin (P=0.045, Fig. 4a/b) .
PAS staining showed reduced myocyte nuclear density, with compensatory myocyte cellular hypertrophy, in ischemic myocardium after the implantation of ameroid constrictor (Fig. 5a ). Both PQS and aotrvastatin increased myocyte nuclear density (P=0.001 and 0.011, respectively; Fig. 5a-b) , with a statistically greater effect with PQS (P=0.048 vs. atorvastatin; Fig. 5b ). Myocyte diameter was reduced by PQS (P=0.014), but not by atorvastatin (P=0.064, Fig. 5c ).
PQS reversed global protein expression changes caused by CMI
A total of 3, 470 proteins was quantified with mass spectrometry, among which 733 were differentially expressed between subjects with vs. without CMI: 341 proteins were upregulated and 392 proteins were downregulated by at least 20% (P<0.05, Student's t-test) 
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Cellular Physiology and Biochemistry in ischemic myocardium (Fig. 6a) . PQS treatment reversed the majority of these changes ( Fig. 6b) : only 5 out of the 341 upregulated proteins and 2 out of the 392 downregulated proteins remained statistically different than in subjects receiving sham surgery after 1-month PQS treatment (Table S2-S5 ).
Proteins that were differentially expressed between subjects with CMI vs. no CMI but restored by PQS treatment (n=219, Fig. 6a ) were fed into a network pharmacology analysis using the similarity-based target prediction method BATMAN-TCM [22] . The analysis identified 5 putative protein targets of the 5 major PQS components (Rb2, Rb3, Rc, Rd, and F11), including PRKCD, P4HA1, FASN, FGB, and MUT (Fig. 6c) .
PRKCD is the only protein among the 5 candidate targets of PQS that is known to block angiogenesis [24] . Western blot analysis showed increased expression of PRKCD in ischemic myocardium (vs. sham surgery ; Fig. 7a) ; such an effect was reversed by PQS (Fig. 7b) . Immunohistochemistry yielded identical results (Fig. 7c/d) . 
Discussion
To the best of our knowledge, this study represents the first study that demonstrated beneficial effects of PQS in a large animal model of CMI. The most important finding is improved myocardial function as reflected by increased LVEF% and WT% by both PQS and atorvastatin. The second major finding is improvement of glucose utilization in ischemic myocardium by both PQS and atorvastatin. Both PQS and atorvastatin increased density of arterioles and myocyte nuclei. However, cardiac hypertrophy, as reflected by myocyte diameter change, was ameliorated only by PQS. Another preliminary but potentially important finding is the likely involvement of PRKCD in the reversal of CMI-induced protein expression changes by PQS.
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F-FDG PET imaging reflects the rate of cellular glucose uptake. Myocardial uptake of glucose is dependent on serum insulin [25] . Consistent with previous studies that showed decreased insulin-dependent glucose uptake by the heart [26] , we showed decreased glucose uptake in mini pigs receiving ameroid constrictior. PQS clearly improved glucose utilization in ischemic area, as evidenced by decreased SRS, SRS%, TPD% and PDE% in comparison to subjects with CMI but receiving no drug treatment. In addition, MSI in all four measured segments (e.g.,mid-anteroseptal, apical septal, apical anterior, and apical inferior) was increased significantly by PQS, indicating improved regional glucose metabolism.
Neovascularization and remodeling of the preexisting vasculature are hallmark features in CMI. Remodeling is regulated by local pro-angiogenic factors, inflammatory reactions and vascular progenitor cells, and critically affects the long-term functional outcomes of the ischemic area [27] . Promoting myocardial angiogenesis is a promising approach for the treatment of CMI [28] . In the current study, arteriole density was significantly increased by both PQS and atorvastatin, thus supporting the functional improvement of myocardial function. It is noteworthy that the magnitude of change in arteriole density was greater with PQS treatment than with atorvastatin. This may explain the greater improvement in WT% and SRS% with PQS. Consistent with previous studies [18, 29] , myocyte nuclear density was increased by PQS. Treatment with PQS attenuated the cellular hypertrophy, indicating that PQS improve oxygen transport across the sarcolemma in the ischemic myocardium [30] .
PQS treatment altered the global protein expression in AAR myocardium. Such effects were generally minor (between -2.2 and 2 fold). Majority of the changes induced by CMI was reversed by PQS, suggesting that PQS exerts its action via multiple targets that individually may not be sufficient to produce any meaningful benefits.
PKC, a member of a large family of serine/threonine-specific protein kinase, is associated with pathophysiology of vascular complication [31] and can be activated by signals such as overloading Ca 2+ or diacylglycerol. PRKCD, known as PKCδ in porcine species, belongs to the PKC family and is expressed in endothelial cells (ECs) and smooth muscle cells (SMCs) [32, 33] . A study in rats demonstrated that PKCδ could impair vessel formation in diabetic ischemic limbs [24] , suggesting that PKCδ is a negative regulator of angiogenesis. In our study, we showed PQS could reverse CMI-induced elevation in PRKCD expression, indicating that PQS may promote angiogenesis through blocking the expression of PRKCD.
The current study has several limitations. First, recent studies suggest that heart is capable of self-regeneration [34] . This, continuous growth of the mini-pigs used in the current study could be a confounding factor that contributed to the improvement of cardiac function and myocardial metabolism. Second, the treatment period was only 1 month in the current study. Long-term effect of PQS on cardiac function needed to be investigated in the future. Third, previous studies had demonstrated PQS could interact with phenelzine and warfarin [35] . The current study did not examine whether PQS and atorvastatin interact at a pharmacokinetic level. As a result, further studies are needed before PQS could be used in subjects also receiving atorvastatin Lastly, analysis with BATMAN-TCM only provided a preliminary set of potential targets. These targets require validation and further investigation. 
Conclusion
One month of PQS treatment could improve cardiac function and glucose utilization in a swine model of CMI, possibly by reversing global protein expression changes caused by CMI.
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